To identify the subset of cancer patients responsive to immunotherapies, certain biomarkers have been discovered, including PD-L1 expression (Davis and Patel, 2019), mismatch repair deficiency (Le et al., 2015), and high tumor mutation burden (TMB) (Goodman et al., 2017). This evidence concerns the gene CD274 and neoplasm.